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Abstract
Background and Purpose: Outcome in patients hospitalized for acute stroke varies considerably be-
tween populations. Within the framework of the GAIN International trial, a large multicenter trial of a
neuroprotective agent (gavestinel, glycine antagonist), stroke outcome in relation to health care resource
use has been compared in a large number of countries, allowing for differences in case mix.
Methods: This substudy includes 1,422 patients in 19 countries grouped into 10 regions. Data on
prognostic variables on admission to hospital, resource use, and outcome were analyzed by regression
models.
Results: All results were adjusted for differences in prognostic factors on admission (NIH Stroke Scale,
age, comorbidity). There were threefold variations in the average number of days in hospital/institutional
care (from 20 to 60 days). The proportion of patients who met with professional rehabilitation staff also
varied greatly. Three-month case fatality ranged from 11% to 28%, and mean Barthel ADL score at
three months varied between 64 and 73. There was no relationship between health care resource use
and outcome in terms of survival and ADL function at three months. The proportion of patients living at
home at three months did not show any relationship to ADL function across countries.
Conclusions: There are wide variations in health care resource use between countries, unexplained
by differences in case mix. Across countries, there is no obvious relationship between resource use
and clinical outcome after stroke. Differences in health care traditions (treatment pathways) and social
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context seem to be major determinants of resource use. In making comparisons between countries,
great care should be exercised in using outcome variables as indicators of quality of stroke care.
Keywords: Health care resource use, Length of hospital stay, Survival, Functional outcome
Stroke places a heavy burden not only on the person affected but also on the family, the
health care system, and the society at large. Among people over 45 years of age, stroke is the
leading cause of disability-adjusted life years (DALYs) lost worldwide (14;15). In affluent
countries, stroke ranks third, behind ischemic heart disease and depression, as a cause of
DALYs lost with all age groups included (15). The burden on the health care system and
social services includes hospitalization, supportive and residential care, and rehabilitation,
with hospitalization and other institutional care representing a major component of the cost
burden, particularly over a shorter time frame (5–7;20;26). The provision of stroke care
differs markedly between countries and national regions (3;9;22;25). Accordingly, estimates
of resource use and cost of stroke have reported large variations between different countries.
Much of this variation can be ascribed to differences in the costs included (for instance,
whether or not indirect costs have been taken into account) and different methodologies
used to collect data (6;7).
Stroke outcome also varies very considerably between regions and countries. In the
WHO MONICA Project, in which a uniform methodology has been applied in 15 popu-
lations in Europe and China, early case fatality varied threefold between countries (23).
Similar large differences in case fatality during the acute phase were observed in a Euro-
pean Union survey of stroke management, and the very large differences were only partly
explained by differences in case mix (24;25). The European Stroke Care Inventory found
higher 30-day case fatality in Eastern European countries compared with Western European
countries (1). More than twofold variations in six-month case fatality were observed in the
International Stroke Trial, and the differences persisted after adjustment for case mix (21).
For persons surviving a stroke, few multinational comparisons of stroke outcome using
uniform data collection procedures have been reported (3;9;21). Different functional out-
comes may depend on age at stroke, co-morbidity, severity of the stroke, and possibly also
gender (10). Both survival and functional outcome may also be affected by medical inter-
ventions in the acute phase and early rehabilitation, most convincingly shown in randomized
trials of stroke units vs. stroke care in general wards (11).
In this report, we use data collected within the framework of a multinational clinical trial
of gavestinel, a glycine antagonist, in patients with acute ischemic stroke (12) to describe
regional/national differences in health care resource use, survival, and functional outcome.
Possible explanatory factors for these differences are explored, such as patient differences
in baseline characteristics and stroke severity, the duration of treatment in hospital and use
of other care in hospital, and posthospital discharge disposition.
METHODS
These data were collected as part of a multinational clinical trial conducted in 21 countries to
evaluate the safety and efficacy of adding treatment with gavestinel (GV150526), a newly
developed neuroprotective therapy against cerebral damage, to standard care after acute
ischemic stroke (12). There were no significant differences between treatment groups in
survival or functional outcomes at three months after stroke for patients with confirmed
ischemic stroke (12). Therefore, data from the active treatment and placebo groups have
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been pooled in the present study when comparing the three-month burden of stroke care
and treatment across national regions.
The GAIN International study, including collection of data on resource use, was ap-
proved by all local or national ethical committees concerned. Written or witnessed oral
consent to take part in study was obtained for all participants, either from the patient or
from his/her representative.
Previously functionally independent persons presenting to hospital within six hours of
onset of symptoms of a moderately severe stroke were entered in the study, unless subarach-
noid hemorrhage was diagnosed or suspected. A total of 1,804 patients were randomized
and admitted to hospital for a minimum three-day ward stay. All patients had CT or MRI
scan within first 18 hours to confirm stroke type (ischemic or hemorrhagic). The ward type
and other care in hospital and after discharge were at the discretion of the treating clinician.
Patients were assessed at hospital discharge or seven days after randomization and followed
at one and three months after discharge for survival and functional outcome as assessed
by the Barthel ADL index (13). Information on residence, employment status, and paid
and unpaid home assistance were collected both at baseline and at three-month follow-up.
Data on health care resource use, such as length of stay in hospital, rehabilitation facility
or assisted living environments, number of rehabilitation sessions as inpatient and outpa-
tient, and number of outpatient visits to a physician, were also collected at the three-month
follow-up.
The present study was restricted to patients in the GAIN International study that had
ischemic stroke. Due to the small numbers of patients (22 and 11, respectively) and no
obvious grouping partner(s), South Africa and Israel were not included in further compar-
isons. To improve the statistical power, some of the remaining 19 countries with a relatively
small number of patients included in the study were grouped together, resulting in 10 re-
gions/countries (Table 1). The grouping was based on geography (neighboring countries),
and on similarities in OECD data on health indicators (life expectancy), health care re-
sources (number of inpatient beds per capita, expenditure on health per capita), and similar
social services for elderly and disabled people (16). Each of the 10 regions/countries was
represented by 4–30 different hospitals (mean 17). Primary intracerebral hemorrhage was
Table 1. Patient Characteristics on Admission to Hospital for Acute Stroke by National
Region
Concomitant disorders
Stroke
Age, Previous severity
proportion Atrial myocardial (NIHSS at
>75 years Male Diabetes fibrillation infarction baseline)
Country/region N (%) sex (%) (%) (%) (%) mean ± SD
Australia/New Zealand 137 34 56 21 32 15 14.1 ± 6.7
Austria/Germany 158 39 57 27 28 14 10.0 ± 5.3
Belgium/Netherlands 294 40 56 17 29 17 13.7 ± 6.2
Denmark/Finland/ 203 38 59 10 28 17 12.8 ± 5.8
Iceland/Norway/
Sweden
France 142 32 63 10 27 16 14.7 ± 5.9
Greece 72 39 58 19 38 6 12.0 ± 6.1
Hong Kong/Singapore 85 32 49 38 28 14 12.5 ± 7.8
Italy 117 45 56 17 26 12 11.8 ± 6.2
Portugal/Spain 128 46 52 26 37 4 14.6 ± 6.1
United Kingdom 86 38 52 8 29 22 13.6 ± 6.5
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present in 333 patients. In 16 patients, the drug was not given and participation in the trial
was terminated early. After these exclusions, 1,422 patients with acute ischemic stroke
remained in the present study.
Stroke outcomes of survival, survivors’ living setting at three months, and mean Barthel
ADL score were compared across regions. Regions were first compared on observed out-
comes, then outcomes after adjusting for differences in patient case mix, and finally out-
comes after adjusting for differences in hospital duration as well as case mix. The variables
used to adjust for case mix were sex, age, severity of stroke on admission to hospital (mea-
sured by NIH Stroke Scale) and comorbidity (atrial fibrillation, diabetes, and history of
myocardial infarction). In some models, outcome was also adjusted for length of hospi-
tal stay, as described in the appropriate tables. Regression procedures were used to select
meaningful explanatory variables. Thus, for each outcome, stepwise regression (logistic re-
gression for categorical outcomes) was used to select variables that contribute significantly
to variability between regions, and the overall effect of region was tested after entering
all meaningful explanatory variables. Models were fitted, and adjusted least squares mean
estimates were calculated for quantitative outcomes (mean Barthel score) using SAS pro-
cedure GLM. SAS was also used for logistic regression models that were fitted for binary
outcomes (survival, living at home at three months). The levels of statistical significance
were adjusted for multiple comparisons.
RESULTS
Case Mix
Table 1 displays the patient case mix on admission to hospital for acute stroke in each of
the 10 regions/countries. Whereas gender distribution and the severity of stroke showed
only small or moderate differences between the regions/countries, there were considerable
variations in age structure and presence of comorbidity. Therefore, in the following analyses,
outcome data are presented both unadjusted and adjusted for case mix on admission to
hospital.
Health Care Resource Use
In Figure 1, the regions/countries are ranked by the mean time survivors spent in institutional
care during the first three months after stroke. The total number of hospital days was found
to be statistically significantly different between regions (p value <.0001). The duration of
hospital stay was about twice as long in the UK and Belgium/The Netherlands compared
with the Mediterranean countries (Greece, Italy, and Portugal/Spain). When all institutional
care during the first three months was combined, there were, after adjustment for case
mix at onset of stroke (sex, age, NIH Stroke Scale at baseline, atrial fibrillation, diabetes,
and previous myocardial infarction), threefold differences between the countries with the
shortest (Greece 20.3 days) and the longest institutional stay (Austria/Germany 60.6 days
and France 60.0 days).
As shown in Table 2, regions were also found to differ significantly in the proportion
of patients to receive inpatient and outpatient rehabilitation (p value <.0001). The propor-
tions treated in hospital by physiotherapists, occupational therapists, and speech therapists
were considerably smaller in France, Greece, Italy, and Portugal/Spain than in the other
participating regions/countries.
After discharge from hospital, there were also very marked differences between re-
gions/countries in the proportion of survivors who had access to outpatient rehabilitation
during the period from discharge to follow-up at three months (Table 2). Physiotherapy
and speech therapy were provided more often in Belgium/The Netherlands and Australia/
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Figure 1. Mean length of initial hospital stay and other institutional stay during the first three
months after stroke by region/country. Data were restricted to patients surviving the first
90 days and were adjusted for differences in case mix on inclusion into the GAIN International
trial.
New Zealand than in the other regions/countries. Outpatient occupational therapy was
nonexistent in the Greek and Italian centers, whereas more than half of the survivors were
treated by an occupational therapist as outpatients if they had been discharged from a
hospital in Australia/New Zealand.
Outcome in Relation to Case Mix and Health Care Resource Use
There was a statistically significant difference in survival at three months across regions
(Table 3) that remained after adjustment for the case mix of patients (p value =.0001;
variables that contributed significantly to the model are given in the table) as well as after
adjustment for both case mix and duration of the initial hospital stay (p value =.0001).
Table 2. Inpatient and Outpatient Rehabilitation
Percentage of patients Percentage of patients
with inpatient with outpatient
O.T./ Speech Other O.T./ Speech Other
Physio therapy therapy Physio therapy therapy
(%) (%) (%) (%) (%) (%)
Australia/New Zealand 93 81 60 73 25 14
Austria/Germany 78 41 12 28 4 4
Belgium/Netherlands 85 54 9 72 32 5
Denmark/Finland/Iceland/ 77 22 7 47 10 6
Norway/Sweden
France 54 19 4 39 14 5
Greece 44 1 0 55 7 5
Hong Kong/Singapore 88 62 0 42 14 0
Italy 47 16 3 32 13 1
Portugal/Spain 57 7 2 49 8 0
United Kingdom 86 58 10 35 17 4
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Table 3. Survival to Three Months
Survival to three months
Adjusted for Adjusted for case
Country/region N Observed (%) case mixa mix, hospital LOSb
Australia/New Zealand 137 87 89 88
Austria/Germany 158 85 80 78
Belgium/Netherlands 294 77 79 74
Denmark/Finland/Iceland/ 203 78 77 78
Norway/Sweden
France 142 71 72 74
Greece 72 82 80 86
Hong Kong/Singapore 85 89 89 91
Italy 117 82 81 86
Portugal/Spain 128 80 85 90
United Kingdom 86 79 80 75
a Adjusted for case mix (age, NIH Stroke Scale at baseline, atrial fibrillation, prior myocardial infarction.
b Adjusted for case mix as well as total number of days in initial hospitalization. LOS, length of stay.
When compared with France (lowest survival), survival was significantly higher in Italy,
Portugal/Spain, Australia/New Zealand, and Hong Kong/Singapore.
For patients surviving to three months, the functional outcomes shown as categories
of the Barthel score and the proportion of patients living at home at three months are
shown in Table 4. There was a considerable variation in mean Barthel scores at follow-up,
ranging from 59 to 73 points. After adjustment for case mix at onset of stroke (variables that
contributed significantly to the model are given in the table), this variation was considerably
reduced (64 to 73 points) and did not reach statistical significance (p value =.255). On
the other hand, there was a statistically significant (p value <.0001) difference in place
of living at three months across regions with the lowest proportion of surviving patients
Table 4. Stroke Survivor Outcomes at Three Months: Mean Barthel ADL Scores and Pro-
portion Living at Home
Barthel ADL score, Proportion of patients living
mean points at home at 3 months
Adjusted for Adjusted for
Country/region N Observed case mixa Observed (%) case mixb (%)
Australia/New Zealand 119 70 73 60 63
Austria/Germany 135 73 64 66 58
Belgium/Netherlands 227 64 67 49 52
Denmark/Finland/Iceland/ 159 73 71 59 58
Norway/Sweden
France 101 70 71 56 57
Greece 59 71 68 95 92
Hong Kong/Singapore 76 70 69 78 76
Italy 96 72 70 80 78
Portugal/Spain 102 59 67 74 80
United Kingdom 68 71 72 69 70
a Adjustment variables chosen by logistic regression forward selection were age, baseline NIH Stroke Scale score,
and diabetes.
b Adjustment variables chosen by logistic regression forward selection were age, baseline NIH Stroke Scale score,
and history of myocardial infarction.
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Figure 2. Relationship between mean Barthel score and the proportion of surviving patients
living at home at three months follow-up. Unadjusted data.
living at home in Belgium/The Netherlands and the highest proportion in Greece (Table 4).
There was, however, no relationship at all between functional outcome (Barthel index) and
the proportion of survivors living at home three months after their stroke (Fig. 2). With
the same mean Barthel index (unadjusted), the proportion living at home ranged from 39%
in France to 78% in Greece. In Portugal/Spain, with the poorest functional outcome, the
proportion at home at three months was considerably higher than in the Nordic countries
with the highest mean Barthel score at follow-up.
Across regions/countries, functional outcome in survivors measured as Barthel score
at three months adjusted for case mix did not correlate with resource use in terms of length
of initial hospital stay, also adjusted for case mix (Fig. 3, left panel), or total time spent in
Figure 3. Relationship between length of initial hospital stay (left panel) or total length of
institutional stay (right panel), both adjusted for differences in case mix at onset of stroke,
and mean Barthel index at three months’ follow-up, adjusted for case mix. The variables
used for adjustment of case mix were sex, age, stroke severity on admission to hospital,
presence of atrial fibrillation and diabetes, and history of myocardial infarction.
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institutional care (Fig. 3, right panel). For instance, with the same length of hospital stay
(20 days), mean Barthel score at follow-up ranged from 55 in Portugal/Spain to 71 in Italy.
DISCUSSION
To make multinational comparisons of health care resource use and outcome in patients
presenting with ischemic stroke, we have used data collected within a setting of a three-
month clinical trial. The strengths of the study include (1) the prospective data collection
with uniform predefined criteria for various type of resources used, and (2) the careful
clinical assessment of all patients at entry into the study and during follow-up, which made it
possible to perform detailed adjustments for differences in case mix. The GAIN International
trial was conducted to the highest standards and, despite the failure to demonstrate any
beneficial effects of the glycine antagonist gavestinel, it has been regarded as a model stroke
trial (8).
The present results may not be entirely representative for the general stroke population
or for the care of stroke patients in the participating countries. First, the GAIN International
study protocol excluded patients with mild and very severe symptoms at onset. Second,
participation in a clinical trial may sometimes preclude very early discharge from hospital
because of the need to collect follow-up data. Third, there may be intangible reasons for
patients in a clinical trial to receive care that is different from routine stroke management.
Fourth, centers participating in an international randomized trial on acute stroke are not nec-
essarily representative of their regions/countries. It is reasonable to assume, for instance,
that the intensity of rehabilitation is greater for centers that participated in GAIN Interna-
tional than the average for each region/country. However, the large number of participating
centers (average 17 per region/country) reduces the risk that a single nonrepresentative cen-
ter affects the results from a particular region/country. Combining some of the countries,
each with a limited number of patients, into regions serves the same purpose. Geographically
neighboring countries with similar health care systems were grouped together.
In all estimates of the costs of stroke, the dominant component, by far, is hospital and
institutional care, in particular during the first months after stroke (3;6;7;20). Other direct
costs, such as those for currently available drugs, outpatient visits, and social services con-
tribute a relatively small share. Also indirect costs incurred by early death, early retirement,
and sickness benefits play a minor role early after stroke, because most patients are elderly
(20). The straightforward approach used in this study to compare health care resource use
between regions/countries by length of hospital and other institutional care, therefore, cov-
ers a very large proportion of the total costs. Measuring the input of rehabilitation staff
should, in the present study, be regarded as reflecting access and ambitions in an important
component of stroke management, rather than being an important contributing factor to
total costs.
Statistically significant differences between national regions were found in patient
survival, which remained after adjustment for age, stroke severity, risk factors, and duration
of stay in initial hospitalization. After adjustment for prognostic factors at entry into the
trial, three-month case fatality was more than twice as high in France, Belgium/Netherlands,
and the UK compared with regions/countries with the lowest case fatality rate (Australia/
New Zealand, Portugal/Spain, and Hong Kong/Singapore). Previous direct comparisons
based on hospital- based series of stroke patients (9;25) and patients participating in clinical
trials (3;4;21) have consistently indicated that case fatality is high in the UK when compared
with other Western countries, even after adjustment for known prognostic factors. In contrast
to the present findings, case fatality has been low in the Nordic countries in previous
international comparisons (9;21;23), and our observations of a relatively high case fatality
in France and Belgium/Netherlands have not been documented in other studies.
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The very low case fatality rates observed in some of the regions/countries, particularly
Hong-Kong/Singapore, Portugal/Spain, and Australia/New Zealand are noteworthy and en-
couraging. This finding may well reflect excellence in stroke care, but other explanations
must also be considered. There may be differences in the natural history of ischemic stroke
or case mix that are not reflected by prognostic indictors measured in the present trial (age
and sex, stroke severity as measured by the NIH scale, and comorbidity). For instance,
it has been reported that a high proportion of patients with ischemic stroke have lacunar
infarcts in East Asian populations (19) compared with Caucasian populations (18). This
finding may affect the prognosis independently of the severity of neurological symptoms
at onset as measured by the NIH scale. As another putative explanation, there may have
been differences in the socioeconomic of the stroke patients between the regions with ef-
fects on the clinical course. In some regions/countries with private hospitals participating
in the GAIN International trial, there may have been a selection of relatively affluent pa-
tients, whereas in countries with publicly financed health care systems patients may have
been more unselected. It should be pointed out, however, that it has been more difficult to
demonstrate an effect of social class on the clinical course of stroke than of myocardial
infarction (17).
As discussed in detail by Weir et al. (21), it is unlikely that very large variations in case
fatality (as in the International Stroke Trial) can be explained solely by variations in the
quality of stroke care. Much of the variation can probably be attributed to differences in
unmeasured baseline variables. There is also the possibility that differences in diagnostic
criteria and detection of comorbidity (such as diabetes and previous myocardial infarction)
may have influenced, to some extent, the case mix adjusted case fatality rates.
For patients surviving to three months, functional outcome measured by the Barthel
ADL index was shown to vary considerably between regions/countries, although less so after
adjusting for the patient case mix at onset of stroke. Among interventions in the acute phase
of stroke, dedicated stroke units have been best documented to affect functional outcome
after stroke (11). To what extent the apparently good functional outcome in some regions
in the present study can be ascribed to good access to stroke units cannot be determined,
because data on the proportions of patients that were cared for in stroke units were not
systematically collected.
In some countries, particularly in Greece, Portugal, and Spain, a large proportion of
surviving patients were managed at home by their families, despite being severely ADL-
dependent, whereas in the Nordic countries and France, these patients were usually in
institutional care. Comparing costs for institutional care and home care by families is
notoriously difficult. The limited data available in the scientific literature suggest, however,
that costs for home and institutional care for patients with severe disability after stroke are
of similar order of magnitude (2). Our results agree with observations in the multinational
lubeluzole trials (3;4) in that a relatively high proportion of patients are in institutional
care at three months follow-up in the Nordic countries and in Austria/Germany. The most
evident difference between the GAIN International and the lubeluzole trials were observed
for France, with a high proportion of patients in institutional care at three months in our
study but relatively low proportion in the lubeluzole studies. The two lubeluzole trials did
not recruit patients in the countries with a very low use of institutional care in the present
study (Greece, Portugal, and Spain).
There was no apparent relationship across regions between resource use, in terms
of length of hospital or other institutional stay, and functional outcome. Similarly, there
was no relationship between mean ADL proficiency and the proportion living at home at
three months after stroke. Together, these observations indicate that differences in health
care culture/traditions are major determinants of the extent of resources used for stroke
care, rather than the patients’ condition. For instance, in-hospital rehabilitation is approved
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before starting in fixed sets of multiples of 15 working days in Germany, whereas the length
of in-hospital rehabilitation is more flexible and dependent on the patient’s progress in many
other countries.
The access to outpatient rehabilitation and institutional care for severely disabled per-
sons is another obvious determinant of total use of resources. Cost-effectiveness compar-
isons of stroke care between countries with different health care systems will continue to
be problematic, as long as an incomplete range of costs is measured and a truly societal
perspective fails to be applied. When making multinational comparisons of the burden of
stroke, the burden on the family seems to be a crucial, but hitherto a much neglected compo-
nent. Nevertheless, our failure to demonstrate any clear relationships between health care
resource use and outcome, whether in terms of survival or ADL function, indicates that
those involved in organizing stroke services and in caring for stroke patients in different
countries have a great deal to learn from each other to develop their own stroke services in
a cost-effective manner.
We conclude that there are wide variations between regions/countries in both health care
resource use for stroke care and short-term outcome of stroke patients. Most of these varia-
tions remain after adjustment for case mix on hospital admission. The adjusted case fatality
differences are substantial and merit further exploration. There is, across regions/countries,
no apparent relationship between health care resource use in terms of length of hospi-
tal/institutional stay or access to rehabilitation and outcome measured as survival or ADL
function at three months after stroke. Instead, it seems that variations in the resources used
for stroke care reflect, to a large extent, differences in health care culture/traditions and in
societal context, such as access to long-term institutional care for severely disabled stroke
patients and the involvement of family members in long-term stroke care. Finally, as amply
pointed out by the International Stroke trial investigators (21), there is a need for caution
in the interpretation of comparisons between countries of observational (nonrandomized)
data on outcome after stroke.
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